SAN DIEGO, CA--(Marketwire - Mar 11, 2013) - PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, has engaged Liolios Group to lead a new investor relations and financial communications campaign.
"Our SDC molecule quickly and completely eliminates the triple threat of viruses, bacteria and fungus, yet is 'generally recognized as safe' as a contact biocide," said Michael L. Krall, president and CEO of PURE Bioscience. "Our focused technical sales strategy is creating increasing market recognition and acceptance of our patented PURE™ products across a broad range of industries and applications."
"Given this growing momentum, we believe it's an ideal time to engage the Liolios Group team of experienced investor relations professionals to communicate our developing story to the investment community and help navigate the capital markets," continued Krall. "Liolios Group brings a proven track record of helping companies like PURE to deliver the right message to the right audience, and we intend to leverage its capabilities to build new, high-quality, long-term relationships in the financial community."
Liolios Group will collaborate with PURE Bioscience management to strengthen the company's investor communications activity and expand its interaction with the investment community.
One of the many products based upon the company's SDC technology platform includes the EPA-registered PURE™ Hard Surface disinfectant and food contact surface sanitizer. PURE Hard Surface provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial kill times and 24-hour residual protection. It completely kills resistant pathogens like CRE and MRSA, while also effectively eliminating dangerous fungi and viruses, including HIV, Norovirus, Influenza A, Avian Influenza and H1N1. PURE Hard Surface is registered for use on food contact surfaces and is gentle enough to be used near children.
For more information about PURE Bioscience, contact Liolios Group at 949-574-3860 or email PURE@liolios.com.
About Liolios Group, Inc.
Liolios Group is a highly selective and comprehensive investor relations firm specializing in small and micro-cap companies. The firm aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage, and capital attraction. Founded in 1999, Liolios Group executives have extensive experience in finance and investments, and represent clients in a wide range of industries, including life sciences/healthcare, consumer/Internet retail, business services, digital media/software, clean technology, technology and natural resources/special situations. For more information about Liolios Group, visit www.liolios.com.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "expect," "intend," "project" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed initiatives and business plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.